Early results suggest benefit of dual PARP and PD-L1 inhibition in metastatic breast cancer patients carrying germline BRCA mutations

Analysis of a phase III study highlights the prognostic value of molecular classification in high-risk endometrial cancer

Patients with locoregionally advanced squamous cell carcinoma of the head and neck could benefit from the addition of the apoptosis inhibitor antagonist Debio 1143 to first-line chemoradiotherapy

Phase II data point to durable responses with combination immunotherapy in certain subsets of advanced biliary tract cancers

Restrictive measures to control the spread of COVID-19 have adverse effect on continuation of radiotherapy in patients with cancer

The PD-L1 inhibitor avelumab might help some women with gestational trophoblastic tumours avoid combination chemotherapy

Second-look surgery and hyperthermic intraperitoneal chemotherapy may not improve colorectal cancer peritoneal metastases outcomes compared with standard surveillance 

Adding locoregional radiotherapy to chemotherapy may improve overall survival for patients with de novo metastatic nasopharyngeal carcinoma